Merck (MRK) Launches ENHANCE-3 Phase 3 Trial for COPD Treatment
Merck (MRK) Launches ENHANCE-3 Phase 3 Trial for COPD Treatment GuruFocus
Covered in this story
Analyst targets on Merck & Co.
- Freedom Broker: $149 → $140 by Nov 2027 via Investing.com Canada
- Guggenheim: $150 → $171 by Oct 2027 · Buy via Investing.com
- RBC Capital Markets: $145 → $145 by Oct 2027 · Sector Perform via MarketBeat
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $MRK yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Merck & Co. →Dalsna Finance is currently tracking 32 stories mentioning Merck & Co., the earliest published 12 Jun 2026.
Summary aggregated from GuruFocus's public RSS feed. The full reporting belongs to GuruFocus — please read it on their site.